Concurrent administration of trastuzumab and anthracyclines as adjuvant regimen for HER2-positive breast cancer: a randomised controlled trial

BACKGROUND: The regimen of concurrent administration of trastuzumab and anthracyclines in the adjuvant treatment of breast cancer has never been evaluated prospectively for fear of cardiac toxicity. METHODS: Patients with HER2-positive operable breast cancer were randomised to receive adjuvant treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Songjie, Xu, Ying, Zhou, Yidong, Mao, Feng, Guan, Jinghong, Sun, Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5696221/
https://www.ncbi.nlm.nih.gov/pubmed/29190955
http://dx.doi.org/10.18632/oncotarget.21579

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5696221/
https://www.ncbi.nlm.nih.gov/pubmed/29190955
http://dx.doi.org/10.18632/oncotarget.21579

Ejemplares similares